Hematology/oncology and stem cell therapy最新文献

{"title":"Acquired factor XIII deficiency in myeloid neoplasms: case series and review of literature.","authors":"Alfadil Haroon, Mostafa F Mohammed Saleh, Ali Alahmari, Syed Osman, Ahmed Alotaibi, Hazzaa Alzahrani, Mahmoud Aljurf","doi":"10.4103/hemoncstem.hemoncstem-D-24-00034","DOIUrl":"10.4103/hemoncstem.hemoncstem-D-24-00034","url":null,"abstract":"<p><p>Acquired factor XIII (FXIII) deficiency is a rare disorder that could be associated with autoimmune and malignant disorders with a high risk of bleeding. In acute leukemias, acquired FXIII deficiency has been reported and replacement of FXIII helped to control significant bleeding. Here, we report four cases of myeloid neoplasms to have acquired FXIII deficiency with interesting concomitant RUNX1 mutation in the molecular background of two patients. Correction of bleeding complications was successful in all patients with FXIII substitution by FXIII concentrate in three patients and cryoprecipitate in one patient. Studying the association of FXIII deficiency with molecular abnormalities in such neoplasms is needed for better understanding and detection of common pathophysiologic pathways. This could help to avoid severe bleeding during diagnostic or therapeutic interventions in patients at risk.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"245-247"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of immature platelet fraction measurement in predicting hematologic recovery in patients with acute leukemias undergoing high-intensity chemotherapy and stem cell transplantation.","authors":"Ana Beatriz Sánchez López, Rolando Humberto Martínez Cordero, Gloria Patricia Duarte Luque, Rose Mary Jaramillo Calle, Melody Mary Lever Hawkins, Lina María Sopó Martínez, Alexandra Porras Ramírez, Alejandro Rico Mendoza","doi":"10.4103/hemoncstem.hemoncstem-D-24-00005","DOIUrl":"10.4103/hemoncstem.hemoncstem-D-24-00005","url":null,"abstract":"<p><strong>Background and objectives: </strong>The immature platelet fraction (IPF) count is a parameter that quantifies young and reticulated platelets in peripheral blood, which reflects platelet production in the bone marrow. It has been used as a predictive model for bone marrow recovery in patients with acute leukemia after high-intensity chemotherapy and/or stem cell transplantation. This study aimed to evaluate IPF as a predictor of hematologic recovery in these patients.</p><p><strong>Materials and methods: </strong>A retrospective analysis of patients with acute leukemias after high-intensity chemotherapy or undergoing stem cell transplantation, treated at the Instituto Nacional de Cancerología (INC) (Bogotá, Colombia) between October 2020 and March 2021.The variables studied included age, sex, type of leukemia, type of treatment, type of chemotherapy, treatment duration, peripheral blood platelet count, percentage of IPF (IPF%), and peripheral blood neutrophil count. Univariate and multivariate analyses were carried out to evaluate the relationship between the IPF behavior and hematologic recovery. Statistical analysis was performed using the R package version 4.2.0® (free license).</p><p><strong>Results: </strong>Between October 2020 and March 2021, 32 patients were analyzed, with a median age of 26 years; the male population was 59.4%. Acute lymphoid leukemia was the most frequent type in 62.5%; 43.7% of patients received chemotherapy, while the others underwent allogeneic stem cell transplantation. Hematologic recovery occurred between days 15 and 30. Spearman's correlation was 0.27 with a p=0.13 for recovery day and IPF% (weak correlation).</p><p><strong>Conclusion: </strong>There is limited information regarding the usefulness of IPF% in hematology. The IPF% was not found to be a predictor of hematologic recovery in patients with acute leukemia after chemotherapy and/or allogeneic stem cell transplantation. The lack of correlation does not allow for assuming a reliable cut-off point. Further studies with a larger sample size are needed.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"239-244"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion-associated graft-versus-host disease (TA-GVHD) and graft-versus-host disease (GVHD): Pathophysiology and management (contrasted and compared).","authors":"Serena Valsami, Georgios Dryllis, Kassiani Papanastasi, Styliani Kokoris, Anastasios Kriebardis, Konstantinos Nikitiadis, Konstantinos Konstantopoulos, Marianna Politou","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00043","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00043","url":null,"abstract":"<p><p>Transfusion of blood products is a common lifesaving medical procedure in clinical practice. However, it poses the risk of potential adverse reactions for the recipient. Transfusion-associated graft-versus-host-disease (TA-GVHD) is a rare adverse event, fatal in >90% of cases. TA-GVHD pathophysiology is not completely understood involving two factors: (i) underlying immunosuppression and (ii) human leukocyte antigen compatibility between blood donor and recipient. Clinical presentation is not specific, and the difficulty in correlating the clinical syndrome to the transfusion renders diagnosis challenging. As no effective treatment exists to date, irradiation of blood products remains the cornerstone of TA-GVHD prevention. Distinct differences emerge in comparing TA-GVHD to GVHD, a common event of the bone marrow graft to the recipient after allogeneic hematopoietic stem cell transplantation; thus, GVHD may be a helpful disease model used to better understand TA-GVHD. This is a review of TA-GVHD in comparison with GVHD.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"203-210"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low incidence of primary graft failure with bendamustine, fludarabine, and busulfan conditioning prior to haploidentical allogeneic hematopoietic cell transplantation.","authors":"Ivan Sergeevich Moiseev, Alexandra Nikolaevna Cherkashina, Tatiana Aleksandrovna Rudakova, Nikita Pavlovich Volkov, Dmitrii Konstantinovich Zhogolev, Svetlana Evgenievna Durova, Yulia Yurievna Vlasova, Elena Vladislavovna Morozova, Sergey Nikolaevich Bondarenko, Alexander Dmitrievich Kulagin","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00026","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00026","url":null,"abstract":"<p><p>The outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) have improved with the implication of new in vivo and ex vivo graft-versus-host disease (GVHD) prophylaxis regimens. However, primary graft failure is still reported more frequently in haplo-HCT compared to a matched donor HCT. We conducted a pilot study (NCT04942730) to evaluate the impact of adding bendamustine to fludarabine and busulfan conditioning on engraftment after haplo-HCT. Bendamustine was administered on days -7 and -6 in the 130 mg/m2 dose. Fifty patients with malignant disorders in complete hematologic response were enrolled. The cumulative incidence of engraftment was 98% (95% confidence interval [CI] 77%-99%) with a median of 20 days. One-year overall survival was 67.9% (95% CI 53.2%-86.7%), event-free survival was 68.1% (95% CI 53.4%-86.8%), the cumulative incidence of relapse was 4.9% (95% CI 0.82%-15%), and nonrelapse mortality was 27% (95% CI 13%-44%). Relatively high incidence of viral reactivations (68%, 95% CI: 52%-79%) and invasive fungal infections (19%, 95% CI: 9.3%-32%) were observed. The study justifies further investigation of fludarabine, busulfan, and bendamustine conditioning in haplo-HCT.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"219-226"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"H syndrome: A histiocytosis-lymphadenopathy plus syndrome. A comprehensive review of the literature.","authors":"Alaa Hamad, Hadeel Elwaheidi, Farah Salameh, Mossaed Alyahya, Riad El Fakih, Mahmoud Aljurf","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00004","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00004","url":null,"abstract":"<p><p>H syndrome is a rare autosomal recessive genodermatosis that falls under the histiocytosis-lymphadenopathy plus syndrome. The term \"H syndrome\" includes manifestations such as hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, hypogonadism, low height, and occasionally hyperglycemia. The syndrome is associated with mutations in the SLC29A3 gene, which encodes the human equilibrative transporter 3 present in endosomes, lysosomes, and mitochondria. The generalized and ubiquitous presence of affected lysosomes and mitochondria contributes to the systemic and phenotypically heterogeneous manifestations of the syndrome. H syndrome manifestations are cutaneous, systemic, and organ-specific. The pathognomonic signs are hypertrichosis and hyperpigmentation in the inner thighs and shins. However, not all patients present with these symptoms. H syndrome management involves a multidisciplinary approach to address specific symptoms and complications. The prognosis of H syndrome depends on several factors, including the extent and severity of clinical manifestations, the presence of complications, and timely diagnosis and management. Further studies are needed to explore the association between prognosis and the different mutations encountered in H syndrome.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"159-167"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and outcomes of CAR-T cell therapy recipients with septic shock in the United States.","authors":"Aditya Sharma, Aditi Sharma, Ayman O Soubani","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00031","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00031","url":null,"abstract":"","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"200-202"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rehabilitation practices during hematopoietic stem cell transplantation: An international survey.","authors":"Victor F Leite, Sonal Oza, Sara C Parke, Toure Barksdale, Aliea Herbert, Vishal Bansal, Jae Yong Jeon, Orla McCourt, Shinichiro Morishita, Mahmoud D Aljurf, Jack B Fu, An Ngo-Huang","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00007","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00007","url":null,"abstract":"<p><strong>Background and objective: </strong>Rehabilitation therapy plays an important role in treating physical and functional impairments observed in individuals undergoing hematopoietic stem cell transplants (HSCT). This study assessed the rehabilitation practices implemented in the HSCT population internationally.</p><p><strong>Materials and methods: </strong>A 48-question online survey comprising questions soliciting information regarding patient characteristics, therapy details (timing, indication, and administering providers), outcome measures, and precautions were developed by an international group of cancer rehabilitation physicians. As reported by European registries, surveys were administered to personnel providing care to patients receiving HSCT at cancer centers, which comprised the top 10% of HSCT volume. In addition, emails were sent to National Medical Societies and registries in the Latin America, Asia, and Pacific regions.</p><p><strong>Results: </strong>Forty-three institutions from 18 countries responded to the survey. Half of the centers provided referrals for rehabilitation therapy at the time of admission. Referrals were provided for functional decline (84.5%), risk of falls (53.3%), and discharge planning (42.2%). Rehabilitation therapies were administered by physical therapists (93.0%), occupational therapists (34.9%), therapy aides (14.0%), and speech-language pathologists (11.6%). Approximately 95% of the surveyed centers used objective functional measures such as sit-to-stand (46.5%), grip strength (46.5%), and 6-min walk/gait speed (both 34.9%). The blood counts were monitored to determine the appropriateness of the therapy modalities.</p><p><strong>Conclusion: </strong>Rehabilitation practices varied internationally; however, most centers provided skilled therapy during hospitalization for HSCT, utilized objective and patient-reported outcomes, and monitored blood counts to determine the safety of administering therapy.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"176-183"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A flow cytometric approach to compare stem cell apoptosis in aplastic anemia and hypoplastic myelodysplastic syndrome.","authors":"Medhat Ibrahim, Ashraf Khodeary, Shereen P Aziz, Mahmoud G Mahmoud, Asmaa A Abdel-Baset, Tamer Mohamed, Sherif A Sayed","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00008","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00008","url":null,"abstract":"<p><strong>Background and objectives: </strong>Aplastic anemia (AA) is a disease caused by bone marrow (BM) failure. There are many similarities between AA and hypoplastic myelodysplastic syndrome (MDS); hence, differentiating them could be problematic. The current study aimed to use the new technique of flow cytometry as a possible diagnostic tool for AA and hypoplastic MDS.</p><p><strong>Patients and methods: </strong>The BM mononuclear cell (BMMC) and blood samples from 44 participants (17 patients with AA, 13 with hypoplastic MDS, and 14 healthy controls) were collected. The flow cytometric analysis of the cluster of differentiation 34 (CD34) levels and cell apoptosis was performed for all sample types.</p><p><strong>Results: </strong>Patients with hypoplastic MDS showed a high percentage of CD34+ cells with low apoptosis, while those with AA showed a low percentage of CD34+ cells with high apoptosis.</p><p><strong>Conclusions: </strong>Despite the similarity in the clinical presentation of hypoplastic MDS and AA, they are biologically different disorders. Increased CD34+ cell numbers with high viability may provide a useful and accurate tool for the differential diagnosis of hypoplastic MDS from AA.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"184-189"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcomes of Fusarium infections in adult patients after hematopoietic stem cell transplantation: A meta-summary of case reports.","authors":"Leong Tung Ong","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00009","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00009","url":null,"abstract":"<p><p>Fusarium infections have increased, particularly among patients with hematological malignancies and in those receiving hematopoietic stem cell transplantation (HSCT). This meta-summary summarizes the clinical characteristics, treatment, and outcomes of Fusarium infections in HSCT recipients. The PubMed, ScienceDirect, and Ovid SP databases were searched from inception to January 2024 to identify relevant case reports. A total of 31 patients diagnosed with Fusarium infections after HSCT were included. The most common infection sites were the skin and soft tissues (74.2%), blood (54.8%), and lungs (41.9%). Fusarium species complex was identified in 67.7% of the patients, and the most common species was Fusarium solani (51.6%). Of the included patients, 58.1% received antifungal monotherapy, whereas 41.9% received antifungal combination therapy. The overall mortality rate was 74.2%. Cutaneous infection was associated with a low mortality rate. The median time to mortality was 28 days. Fusarium infections commonly present as disseminated infections in HSCT recipients.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"168-175"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Special Report: Summary of the eighth workshop of the worldwide network for blood and marrow transplantation on the status and issues related to hematopoietic stem cell transplantation in near-east countries, held in Pakistan from September 22 to 23, 2022.","authors":"Hildegard T Greinix, Raheel Iftikhar, Qamar Un Nisa Chaudhry, Parvez Ahmed, Murtadha Al-Khabori, Javid Gaziev, Amir Ali Hamidieh, Shahrukh Hashmi, Mohiuddin Khan, Bishesh Sharma Poudyal, Marwan Shaheen, Walid Rasheed, Sebastian Galeano, Yoshihisa Kodera, Dietger Niederwieser, Syed Osman Ahmed, Yoshiko Atsuta, Helen Baldomero, Cristobal Frutos, Minako Iida, Shinichiro Okamoto, Damiano Rondelli, Joseph Schwartz, Adriana Seber, Daniel Weisdorf, Nina Worel, Efstratios Chatzixiros, Mickey Bc Koh, Mahmoud Aljurf","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00011","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00011","url":null,"abstract":"<p><p>The eighth workshop of the Worldwide Network for Blood and Marrow Transplantation (WBMT) was held in Islamabad, Pakistan, from September 22 to 23, 2022, aiming to foster hematopoietic stem cell transplant (HSCT) activity in the World Health Organization (WHO) Eastern Mediterranean Region (EMRO). Participating countries, including Pakistan, Oman, Iran, and Saudi Arabia, reported increased HSCT in the last few years, whereas others from the EMRO and beyond, including Qatar, United Arab Emirates, Nepal, and Bangladesh, started HSCT recently and have developed HSCT programs with excellent results. During educational sessions and open dialog, participating teams and international experts from the WBMT shared their experience and discussed minimum essential requirements for establishing and expanding HSCT in emerging countries, indications for HSCT training and dissemination of knowledge, stem cell donor selection and safety, quality assurance in transplant centers, and the value and importance of transplant outcome databases. International support, collaboration, and local engagement, including government participation and WHO assistance, are valuable in increasing HSCT access worldwide.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 3","pages":"190-199"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}